The Target-backed mattress and bedding brand is floating at the bottom of its range, at a valuation of less than half that of its last funding round.

Tokyo’s Mothers Market has approved an IPO for the business knowledge-sharing platform that would allow CyberAgent, DA Consortium and Mizuho Bank to exit.

Chalmers University of Technology-founded baby ventilation monitor developer Monivent will join the Spotlight Stock Market in an IPO where 60% of shares have advance subscriptions in place.

University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.

The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

The Sanofi-backed cancer therapy developer is set to raise between $140m and $160m in its initial public offering following $226m in funding.

The CNS disorder-focused drug developer has filed to raise up to $125m having raised $226m in funding from backers including Eli Lilly and Access Industries.

The online streaming platform is seeking a reported $50m from existing investors that include JTBC, Yoshimoto Kogyo, MNC, Liberty Global, Sky, PLDT, Zain Group and Hearst.

The GV-backed primary care membership service floated at the bottom of its range but garnered a valution of more than $1.7bn.

Wuxi AppTec and Alphabet are in line to exit the molecule-discovery software provider, which has set the range for its initial public offering.